Sign In
Buy ABSI
$7.41
-0.99 (-11.79%)
At Close: Jun 23, 2026
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
01:12am, Wednesday, 10'th Jun 2026
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
05:22pm, Friday, 05'th Jun 2026
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 20'th May 2026
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generativ
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
08:01am, Friday, 08'th May 2026
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
11:26pm, Thursday, 07'th May 2026
Absci Corporation (ABSI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
04:05pm, Thursday, 07'th May 2026
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling fro
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:11pm, Monday, 04'th May 2026
VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generativ
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
04:05pm, Thursday, 23'rd Apr 2026
VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat
Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
03:40pm, Tuesday, 21'st Apr 2026
Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 08'th Apr 2026
VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat
MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis
01:22am, Thursday, 02'nd Apr 2026
MiMedx Group (NASDAQ: MDXG - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based
Absci Q4 Earnings Call Highlights
03:07am, Thursday, 26'th Mar 2026
Absci (NASDAQ: ABSI) provided a fourth-quarter and full-year 2025 business update on Monday, highlighting early progress for lead candidate ABS-201, expansion into a second indication, and continued i
Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201
02:48pm, Wednesday, 25'th Mar 2026
Absci Corporation is downgraded to Hold due to a lack of differentiation for ABS-101 and a strategic pivot to ABS-201. ABS-101 failed to outperform 2nd-generation TL1A candidates, leading to halted in
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
08:54pm, Tuesday, 24'th Mar 2026
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
